Shilpa Medicare Limited has informed the Exchange regarding Board meeting Outcome held on August 13, 2025.
SHILPAMED · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shilpa Medicare's board approved Q1 FY26 results with mixed performance — consolidated profit after tax surged about 233% YoY to Rs. 46.89 crore on 9.9% revenue growth, but standalone PAT fell 25.8% to Rs. 20.70 crore with total income declining 13.6%. The company declared bonus shares in a 1:1 ratio, capitalizing Rs. 9.78 crore from securities premium, with record date set for September 26, 2025. Previous period results were restated to reflect the merger of wholly-owned subsidiary INM Technologies. The company booked Rs. 5.18 crore of exceptional losses (standalone) for impairment of advances and investments in foreign subsidiaries. The 38th AGM is scheduled for September 23, 2025, and two promoter-group members have sought reclassification to the public category.
The 1:1 bonus doubles the share count but does not change the company's overall value, though it may improve liquidity. Strong consolidated earnings growth is a positive signal, but the weak standalone performance, recurring foreign subsidiary impairments, and promoter-group reclassification may weigh on sentiment.